ONA Therapeutics Strengthens Scientific Leadership Team
Industry veteran in oncology antibody discovery & development…
Novo Holdings Leads US$21M Series A Financing in BI-OMILQ
Funds will be used to support the development of pioneering…
LogicBio Therapeutics Announces Early Clinical Trial Results Demonstrating First-Ever In Vivo Genome Editing in Children
October 18, 2021
Early data from Phase 1/2 clinical trial…
Pyxis Announces Pricing of Upsized Initial Public Offering
CAMBRIDGE, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Pyxis…
Arix Bioscience plc Business Update and Cancellation of Share Buyback
LONDON, 18 October 2021: Arix Bioscience plc (“Arix” or the…
Destiny Pharma: Major US hospital-based clinical trial highlights benefit of nasal decolonization to reduce ICU infections caused by Staphylococcus aureus
Major US hospital-based clinical trial highlights benefit of…
Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes
ALAMEDA, Calif. & CAMBRIDGE, UK – October 14, 2021 – Exelixis,…
Futura Medical plc Board Appointment
Futura Medical plc (AIM: FUM), a pharmaceutical company developing…
MinervaX provides clinical and leadership update
- Completed enrolment of 150 pregnant women in a Phase 2 study…
HEALTHCAP STRENGTHENS SENIOR TEAM
Mårten Steen Promoted to Co-Managing Partner
Expanded team…
Arix today announces the following updates to its Board and Executive team
LONDON, 6 October 2021: Arix Bioscience plc (“Arix” or the…
Centessa Pharmaceuticals Appoints David Grainger, PhD, a Leading Biotech Entrepreneur, as Chief Innovation Officer
Industry veteran with decades of experience in company formation,…
Amber Implants VCFix® spinal system receives US FDA Breakthrough Designation
The Hague, Netherlands, 5 October 2021: Amber Implants, an innovative…
DelSiTech Awarded UnitaidExplore Funding for Innovations in Paediatric Healthcare
DelSiTech Awarded UnitaidExplore Funding for Innovations in Paediatric…
ExeVir Bio BV announces its participation in the 8th Annual Healthtech Investment Forum organized by SACHS Associates taking place virtually 5th-6th October 2021.
Torsten Mummenbrauer, Chief Executive Officer of ExeVir will…
We’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York
